Laurus Labs Limited (LAURUSLABS) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE947Q01028
Key metrics
- Market Cap
- ₹1.01 L Cr
- P/E Ratio
- 91.7
- EPS
- 20.3
- Book Value
- 100.61
- P/B Ratio
- 18.77
- ROE
- 16.36%
- ROCE
- 16.43%
- Debt / Equity
- 0.46
- Net Margin
- 13.22%
- Revenue Growth
- 22.03%
- Profit Growth
- 148.04%
- Dividend Yield
- 0.13%
- 52W High
- ₹1,949.00
- 52W Low
- ₹823.10
- Market Cap Band
- large cap
- Face Value
- 2
Ratios computed from the annual results period ending 2026-03-31.
About Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
- Headquarters
- Hyderabad, India
- Employees
- 7,059
- Promoter Holding
- 32.03%
The full Laurus Labs Limited analysis
Create a free account to open the complete LAURUSLABS deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.